Lead Product(s) : Rifapentine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rifapentine is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Tuberculosis.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 21, 2012
Lead Product(s) : Rifapentine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dolutegravir Sodium,Moxifloxacin,Rifapentine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : ViiV Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
ACTG Launches Tuberculosis Drug Interaction Trial Among HIV Patients
Details : Dolutegravir is a HIV type 1 integrase inhibitor, which is being evaluated in combination with daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen for HIV-associated tuberculosis.
Product Name : Tivicay
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 14, 2024
Lead Product(s) : Dolutegravir Sodium,Moxifloxacin,Rifapentine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : ViiV Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rifapentine,Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Unitaid
Deal Size : Undisclosed
Deal Type : Agreement
Lupin Partners with Global Agencies to Increase Patient Access to Tuberculosis Prevention Treatment
Details : Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price for the treatment of tuberculosis.
Product Name : Rifapentine/Isoniazid-Generic
Product Type : Antibiotic
Upfront Cash : Undisclosed
October 07, 2022
Lead Product(s) : Rifapentine,Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Unitaid
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Rifapentine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rifapentine is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Tuberculosis.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 16, 2020
Lead Product(s) : Rifapentine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rifapentine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : University of Stellenbosch | Johns Hopkins University | Sanofi | University of Cape Town | Chris Hani Baragwanath Academic Hospital | Washington D.C. VA Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Tuberculosis Clinical Trials Consortium Study 35
Details : Rifapentine is a Antibiotic drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Latent Tuberculosis.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 05, 2018
Lead Product(s) : Rifapentine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : University of Stellenbosch | Johns Hopkins University | Sanofi | University of Cape Town | Chris Hani Baragwanath Academic Hospital | Washington D.C. VA Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rifapentine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Sanofi | Centers for Disease Control and Prevention
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers
Details : Rifapentine is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Tuberculosis.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 14, 2010
Lead Product(s) : Rifapentine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Sanofi | Centers for Disease Control and Prevention
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
